Partner
TEL |
+82-2-772-4711 |
E-MAIL |
jinhwan.chung@leeko.com |
|
|
Jin Hwan CHUNG is a Partner in the Corporate Practice Group and specializes in the areas of healthcare/life sciences, anti-trust and general corporate law, including mergers and acquisitions.
He provides legal representation and counsel to numerous leading pharmaceutical and medical devices companies including Archigen Biotech, AstraZeneca, BMS, Bayer, Berna Biotech (Crucell), Daiichi-Sankyo, Eisai, Johnson & Johnson, Janssen, Merck & Co., Mundipharma, Novartis, Novo Nordisk, Takeda, UCB, Boston Scientific, GE Healthcare, Johnson & Johnson Medical and Intuitive Surgical in connection with various transactions and compliance issues. He is one of the highly regarded experts in the area of healthcare compliance issues and a popular lecturer on this matter.
As part of his corporate practice, he has also been involved in numerous mergers and acquisitions deals and has advised domestic and foreign clients on anti-trust issues such as the Korea Fair Trade Commission’s investigation into the pharmaceutical industry since 2006. Mr. Chung currently serves as the co-head of the Healthcare/Life Sciences Team of Lee & Ko.
Education
2008 |
Georgetown University Law Center LL.M |
2000 |
Judicial Research & Training Institute, Supreme Court of Korea |
1994 |
Seoul National University Graduate School of Law (Course Completion) |
1992 |
Seoul National University College of Law - LL.B. |
Work Experience
2022-Present |
Lee & Ko |
2018-2022 |
Bodyfriend. Co., Ltd. |
2010-2018 |
Lee & Ko |
2000-2009 |
HMP Law |
Expertise
Corporate Governance |
Healthcare |
Mergers & Acquisitions |
Corporate |
Antitrust & Competition |
Digital Health |
Tech & AI |
Admissions
Admitted to bar, Korea(2000) |
Admitted to bar, New York(2008) |
Languages
Representative Cases
Healthcare & Life Sciences
- Advise on pharmaceutical, medical device, healthcare, cosmetic, food and dietary food regulations
- Provide antitrust and compliance advice to domestic and multinational pharmaceutical companies, medical device companies and medical institutions
- Advise on alcohol and tobacco regulations
- Advise on drug and medical device pricing & reimbursement under the National Health Insurance system
- Advise on clinical trial related matters
- Advise on corporate transactions of pharmaceutical and medical device industries including:
- - Bayer’s Mercilon business transfer to Alvogen Korea
- - Lotus Pharma’s equity investment in Alvogen Korea
- - Baxter’s spin-off of Baxalta business
- - Shire and Baxalta merger transaction
- - Johnson & Johnson’s acquisition of Pfizer’s consumer healthcare business
- - 3M’s sale of its pharmaceutical business in Korea
- - Celltrion’s acquisition of Hanskin
Corporate
- Advised LS Cable & System Asia on the sale of its stake to investors
- Advised SeAH Steel on tis spin-off of sheet metal business
- Advised SeAH Network on its sale of Dremline to an investor
- Advised Dongwon F&B on its acquisition of a meat processing company
- Advised Sehkoy Semiconductor New Material on its acquisition of UP Chemical
- Advised Bodyfriend on the sale of its stake to investors
- Advised LG Household and Health Care on its acquisition of Diamond spring water
- Advised WPP Group on its acquisition of Korean advertising companies including OSO, Pharmax and Digital Ocean
- Advised CJ on its sale of household business
Fair Trade
- Represent clients in Korea Fair Trade Commission’s investigations into pharmaceutical and medical devices industry
- Represent clients in reverse payment cases
- Represent a client in mobile phone handset collusion investigation
- Represent a client in hotel collusion case
- Represent a client in ramen collusion case
Education
- Advise on establishment foreign educational institution in Korea
- Advise on structural reform of universities in Korea
Publications / Presentations / ETC
- Digital Health (Korea chapter), International Comparative Legal Guides (2023-24)
- Pharma & Medical Device Regulation (Korea chapter), Getting the Deal Trough, Lexology (2022-24)
- The Healthcare Law Review (Korea chapter), The Law Reviews (2022-24)
- Distribution and Marketing of Drugs (Korea chapter): A Global Guide From Practical Law (2018, 2015, Thomson Reuters)
- Practical Law Multi-Jurisdictional Guide: Life Sciences (Korea chapter, 2012-2015)
- “Medical Advertisement and Inducement of Patients” (Legal Times, 2012)
- The International Comparative Legal Guide to Pharmaceutical Advertising (Korea chapter, 2009)
- A Study on the Criteria for Establishing Foreign Educational Institutions in Overseas Countries based on the Analysis of the Criteria for Establishing Universities in Each Country (Co-researcher, Korea Research Foundation, 2020)
- Exit Strategy and Working Manual for Promoting University Structural Reform (Co-researcher, Ministry of Education, 2016)
- Transfer of Management Rights of School Foundation (Principal researcher, Korea University Institute for Higher Education Policy, 2014)
- “Clinical Trials and Compliance”, Joint Seminar by Korean Research-based Pharma Industry Association and Korea Medical Devices Industry Association (2022)
- “CP Issues in Interactions with Patients and Patient Organizations”, Ethical Business Workshop, Korea Pharmaceutical and Bio-Pharma Manufacturers Association (2022)
- “Trends in Government Investigation into the Pharmaceutical Industry”, Breakfast Seminar for Pharmaceutical Industry Executives hosted by Deloitte Korea (2018)
- “Expenditure Report under the Korean Sunshine Act”, Korea Medical Devices Industry Association (2018)
- “One Year after the Implementation of the Anti-Graft Act and Trends in Kickback Investigations”, Korea Medical Devices Industry Association (2017)
- “Key Issues in and Strategy for Contract Negotiations”, Korea Pharmaceutical Advanced Institution (2017)
- “Understanding Global Business Agreements for Pharmaceutical Companies”, Korea Human Resource Development Institute for Health & Welfare (2017)
- “Transforming Risk into Value: How to Respond to the Anti-Graft Act?”, Deloitte World Class Compliance Workshop (2016)
- “Interactions with Patients and Patient Organizations”, Korean Research-based Pharma Industry Association (2015)
- 2015 KRPIA Ethical Business Practice Workshop (panelist)
- “The License-Patent Linkage System and Antitrust Issues), Spring Conference of Korea Society of Food, Drug and Cosmetics (2015)
- “Understanding Domestic and International Regulation on the Advertisement of Medical Services”, Korea Human Resource Development Institute for Health & Welfare (2014)
- 2014 KRPIA Ethical Business Practice Workshop (panelist)
- “Proactive Negotiation in Cross-border Contracts”, Korea Human Resource Development Institute for Health & Welfare (2014)
- “Business Partnership”, Korea Drug Research Association (2014)
- 2013 KRPIA Ethical Business Practice Workshop (panelist)
- “M&A Transactions: Pharmaceutical Industry in Korea”, Conference for Global Alliance and M&A Strategy, Korea Pharmaceutical Manufacturers Association (2013)
- 2012 KRPIA Ethical Business Practice Workshop (panelist)
- “Fair Trade Issues in the Pharmaceutical Industry”, Seoul Bar Antitrust Committee Seminar (2011)
- “Healthcare Regulation Reform and Compliance Issues”, In-House Counsel Forum (2010)
- “Unfair Customer Inducement Issues in the Pharmaceutical Industry”, Seoul Bar (2010)
- “Case Study on Drug Advertising”, Korean Research-based Pharma Industry Association (2006)